Open AccessVitamin D Treatment in Primary Hyperparathyroidism: A Randomized Placebo Controlled Trial
Author(s) -
Lars Rolighed,
Lars Rejnmark,
Tanja Sikjær,
Lene Heickendorff,
Peter Vestergaard,
Leif Mosekilde,
Peer Christiansen
Publication year - 2014
Publication title -
the journal of clinical endocrinology and metabolism
Language(s) - Uncategorized
Resource type - Journals
SCImago Journal Rank - 2.206
H-Index - 353
eISSN - 1945-7197
pISSN - 0021-972X
DOI - 10.1210/jc.2013-3978
Subject(s) - medicine , placebo , cholecalciferol , endocrinology , vitamin d and neurology , primary hyperparathyroidism , bone remodeling , hyperparathyroidism , bone mineral , secondary hyperparathyroidism , urinary calcium , vitamin d deficiency , parathyroid hormone , creatinine , osteoporosis , calcium , alternative medicine , pathology
Low 25-hydroxyvitamin D levels are common in patients with primary hyperparathyroidism (PHPT) and associated with higher PTH levels and hungry bone syndrome after parathyroidectomy (PTX). However, concerns have been raised about the safety of vitamin D supplementation in PHPT.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom